CAMBRIDGE, Mass., December 17, 2020 – Cadent Therapeutics, a privately held clinical stage biopharmaceutical company focused on the development of therapies for the treatment of cognitive, mood, and movement disorders, announced today that it has reached a definitive agreement with Novartis, under which Novartis will acquire all of the outstanding capital stock of Cadent Therapeutics. […]

Categories: In the News

I donated, for my first time, due to being an essential tremor (ET) patient myself and I see it as an opportunity to help others with ET by helping your organization in raising awareness. I have had ET since I was a child and now being 59 years old, I have seen how it affects […]

IETF: Past, Present and Future; Together We Can Make Life Better for People with ET; An Interview with Scholarship Recipient Madison Young.

Categories: Tremor Gram

By Richard Riehl,Freelance Writer Today I agreed to donate my brain to medical science. (I’ll pause here to allow regular readers of my published opinion pieces to stop laughing.) Twenty-two years ago, after an afternoon of heavy yard work, I reached for a cold beer and sat down to rest. As I brought the bottle […]

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Biogen Inc. (Nasdaq: BIIB) and Sage Therapeutics, Inc. (Nasdaq: SAGE) announced that they have executed a global collaboration and license agreement to jointly develop and commercialize zuranolone (SAGE-217) for major depressive disorder (MDD), postpartum depression (PPD) and other psychiatric disorders and SAGE-324 for essential tremor and other neurological disorders.